Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) CEO Sells $210,990.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 19,500 shares of the stock in a transaction on Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the transaction, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at approximately $2,402,213.12. This trade represents a 8.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $11.01 on Monday. The stock has a fifty day simple moving average of $9.40 and a two-hundred day simple moving average of $9.09. Zevra Therapeutics, Inc. has a 1-year low of $6.19 and a 1-year high of $13.16. The firm has a market cap of $617.99 million, a price-to-earnings ratio of -52.43 and a beta of 1.49. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $1.43 by ($1.49). Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. The firm had revenue of $25.88 million for the quarter, compared to the consensus estimate of $22.49 million. Analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Woodline Partners LP increased its position in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after purchasing an additional 476,032 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Zevra Therapeutics by 15.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares during the last quarter. Rubric Capital Management LP increased its position in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after purchasing an additional 740,584 shares during the last quarter. AIGH Capital Management LLC increased its position in shares of Zevra Therapeutics by 82.4% in the first quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after purchasing an additional 649,495 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Zevra Therapeutics by 0.8% in the second quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock worth $10,948,000 after purchasing an additional 9,275 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ZVRA shares. Weiss Ratings reissued a “sell (d)” rating on shares of Zevra Therapeutics in a report on Saturday, September 27th. HC Wainwright started coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 price objective for the company. JMP Securities reduced their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Zacks Research lowered shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.